Information Provided By:
Fly News Breaks for April 9, 2019
Apr 9, 2019 | 08:45 EDT
After Medtronic (MDT) announced that the company has reached a deal with Blue Cross and Blue Shield of Minnesota on an outcomes-based program for the company's Guardian Connect Continuous Glucose Monitoring system, Stephens analyst Chris Cooley said the program could potentially represent an incremental headwind to Dexcom's (DXCM) revenue growth if applied across a larger setting. However, Cooley is maintaining his calendar 2019 and 2020 estimates for Dexcom and keeps an Overweight rating on shares with a $170 price target.